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Abstract
Purpose To examine the associations between pharma-
ceutically treated anxiety and depression present in the year
prior to breast cancer diagnosis and the risk of incident
cardiovascular disease (CVD), while controlling for tradi-
tional cardiovascular risk factors and clinical characteris-
tics in a population-based observational study.
Methods Adult 1-year breast cancer survivors (n = 7227),
diagnosed between 01-01-1999 and 12-31-2010, with no
history of CVD, were selected from the Netherlands Can-
cer Registry. Drug dispensing data were derived from the
PHARMO Database Network and used as proxy for CVD,
anxiety, and depression. By multivariable Cox regression
analysis, we examined the risk associated with pharma-
ceutically treated anxiety and depression for developing
CVD after cancer diagnosis, adjusting for age, pharma-
ceutically treated hypertension, hypercholesterolemia, and
diabetes mellitus in the year prior to cancer diagnosis,
tumor stage, and cancer treatment.
Results During the 13-year follow-up period, 193 (3%)
breast cancer survivors developed CVD. Women pharma-
ceutically treated for anxiety in the year prior to their cancer
diagnosis had a 48% increased hazard for CVD [HR = 1.48;
95% CI 1.05–1.08] after full adjustment. This association
was restricted to breast cancer survivors who were 65 years
or younger. Depression was not associated with CVD risk
[HR = 0.89; 95% CI 0.52–1.53]. Older age [HR = 1.06;
95% CI 1.05–1.08], hypertension [HR = 1.80; 95% CI
1.32–2.46], and hypercholesterolemia [HR = 1.63; 95% CI
1.15–2.33] were associated with an increased hazard for
incident CVD, whereas hormone therapy [HR = 0.59; 95%
CI 0.42–0.83] was protective.
Conclusions Anxiety present in the year prior to breast
cancer diagnosis increases the risk of incident CVD in
1-year breast cancer survivors, after adjustment for
depression, traditional cardiovascular risk factors, and
clinical characteristics.
Keywords Breast cancer survivors  Cardiovascular
disease  Anxiety  Depression  Cardiotoxicity
Introduction
Cardiovascular disease (CVD) is a common comorbidity in
breast cancer survivors [1, 2] and estimated to be respon-
sible for many non-cancer-related mortalities [1]. This is
partly due to aging, yet also a consequence of received
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treatment. The cardiotoxicity of cancer treatment can lead
to the development of a wide range of CVDs, such as
arrhythmias, heart failure, and valvular heart disease [3, 4].
Furthermore, there are similar underlying risk factors for
both breast cancer and CVD, such as obesity and physical
inactivity [5–7].
Incidence rates of CVD in breast cancer survivors vary
depending on the type of treatment and dosage [8]. Even in
individuals who all received the exact same treatment and
dosage not all develop CVD [9]. Hence, additional factors,
other than cardiotoxic treatment, are involved and may
include traditional cardiovascular risk factors, such as
hypertension or diabetes mellitus, as they increase the risk
of CVD in breast cancer survivors [7, 10, 11].
Psychological factors, such as anxiety and depression,
may also increase the risk of CVD in breast cancer sur-
vivors. Several studies have shown that depression and
anxiety are predictive for the development and progression
of CVD in non-cancer patients [12–16]. A meta-analysis
based on 20 studies examining the predictive value of
anxiety for the incidence of CVD in healthy individuals
concluded that anxious patients had a 26% increased risk of
developing CVD and a 48% increased risk of cardiac death
[12]. Furthermore, depression is a risk factor for recurrent
cardiac events, heart failure [13, 14], major adverse cardiac
events [14, 15], and cardiac death [13]. Hence, the Euro-
pean Society of Cardiology included psychosocial risk
factors, including anxiety and depression, in the Guidelines
on Cardiovascular Disease Prevention in Clinical Practice
in 2012 [11]. Moreover, in a previous study among middle-
aged healthy women (similar in age to breast cancer sur-
vivors), anxiety was found to be predictive of cardiac
mortality [16].
CVD is understudied, underdiagnosed, and undertreated
among women, yet we know that there are sex differences
in the pathophysiology of CVD [17]. Simultaneously, levels
of anxiety and depression are more prominent among
female cancer survivors than in males [18]. Nonetheless, to
our knowledge, the association between anxiety and
depression with incident CVD among female breast cancer
survivors has never been studied before. The aim of this
study was therefore to examine the associations between
anxiety and depression present in the year prior to a breast
cancer diagnosis and the risk of incident CVD in 1-year
breast cancer survivors, while controlling for age, tradi-
tional cardiovascular risk factors, tumor stage, and cancer
treatment (i.e., chemo-, radio-, and hormone therapy). We
chose to look at 1-year survivors as cancer treatment is
generally finished within the first year. In addition, we
explored whether the associations between anxiety and
depression with incident CVD risk differed by age, tradi-
tional cardiovascular risk factors, or cancer treatment.
Methods
Procedure and participants
Data from the Southern Region of the Netherlands Cancer
Registry (NCR) were used in this observational cohort study.
The NCR registers cancer diagnosis, stage, and primary
cancer treatment for all newly diagnosed cancer patients and
is maintained by the Netherlands Comprehensive Cancer
Organization [19]. The Southern Region of the NCR covers
an area of 2.4 million inhabitants [19]. For this study, the
NCR was linked to data from the PHARMO Database Net-
work for cancer patients diagnosed from 1998 onwards, and
a detailed description of this linkage is found elsewhere [20].
PHARMO is a large, population-based network of electronic
healthcare databases and combines data from general prac-
tices, pharmacies, and hospitals which are linked on patient-
level though validated algorithms. In this study, the out-pa-
tient pharmacy database comprising healthcare products
prescribed by the general practitioner or specialist was used.
Dispensing records used included information on product
type and date. Drug dispensings are coded according to the
international Anatomical Therapeutic Chemical (ATC)
classification system [21].
Female adult breast cancer patients diagnosed between
01-01-1999 and 12-31-2010 were selected from the NCR.
To obtain information on survival status and date of death,
the NCR was linked to the municipal Personal Records
database. As anonymous observational patient information
was used, this study does not fall under the Medical
Research Involving Human Subjects Act in the Nether-
lands; therefore, this study was exempted from medical
ethics review and no informed consent was required. This
study was performed in agreement with the Declaration of
Helsinki.
Breast cancer survivors who had a history of CVD
medication use (see the definition of CVD in the next
section) in the 12 months prior to their cancer diagnosis
were excluded, as our aim was to examine the risk of
incident CVD following cancer diagnosis. In addition, to
exclude the effect of detecting CVD due to increased
clinical checkups and the direct and sometimes reversible
effects of receiving cancer treatment, breast cancer sur-
vivors who developed CVD in the first year after diagnosis
were also excluded. Follow-up for a diagnosis of CVD
began 12 months after the cancer diagnosis (which was set
as the index date), as primary cancer treatment is generally
finalized within the first year. Hence, we excluded those
who died or were lost to follow-up during the first year.
Follow-up time was measured until onset of CVD, death,
loss to follow-up, or until the end of the study period (31-
12-2010), whichever occurred first.




CVD was defined as having at least two drug dispenses of
cardiac therapeutics (i.e., ATC code C01) at unique dates
within 6 months. Survivors who dispensed two cardiac
drugs with less than 15 days in between were classified as
having CVD only when they had three cardiac dispenses at
unique dates in a 6-month period. We used a strict defi-
nition based solely on using cardiac therapeutics
(ATC = C01) to avoid false classifications of CVD.
Therefore, usage of CVD-related drugs such as diuretics
(C03) or beta-blockers was insufficient to be classified as
having CVD, as these drugs have a broad treatment range
including non-CVD indications.
Psychological factors—anxiety and depression
Drug dispense information for anxiety disorders
(ATC = N05B) and depression (ATC = N06A) during the
12 months prior to the cancer diagnosis was included.
Patients with one or more drug dispensings were catego-
rized as anxious or depressed (yes/no).
Traditional cardiovascular risk factors
Drug dispense information on the traditional cardiovascu-
lar risk factors including hypertension (ATC = C02,
C03A, CO3B (except C03C), C07, C08, C09 (except
C09X)), hypercholesterolemia (ATC = C10), and diabetes
mellitus (ATC = A10) during the 12 months prior to the
cancer diagnosis was captured [22]. Having one or more
drug dispensings for hypertension, hypercholesterolemia,
and diabetes mellitus in the 12 months prior to the cancer
diagnosis was categorized as having traditional cardiovas-
cular risk factors (yes/no). We opted for the inclusion of
these traditional cardiovascular risk factors already present
prior to cancer diagnosis, as cardiotoxic treatment is known
to increase the risk of developing these traditional cardio-
vascular risk factors, which can then be seen as a precursor
of cancer treatment-induced CVD itself.
Age and clinical characteristics
Survivors’ age and clinical information on tumor stage and
treatment (i.e., having received chemo-, radiation-, or
hormone therapy (yes/no)) were obtained from the NCR.
Statistical analyses
Differences in patient characteristics (i.e., age, psycholog-
ical factors, traditional cardiovascular risk factors, and
clinical characteristics) between breast cancer survivors
with and without incident CVD were analyzed using
ANOVA, the v2 test, or Student’s t test for independent
samples as appropriate.
The associations between pharmaceutically treated
anxiety and depression with incident CVD risk were
examined separately and simultaneously using multivari-
able Cox regression analyses. Analyses included covariates
which were entered in separate steps. First, we adjusted for
age (continuous) as a potential confounder. Second, tradi-
tional cardiovascular risk factors (i.e., hypertension,
hypercholesterolemia, and diabetes mellitus) were added to
the model. Finally, clinical information on tumor stage,
chemo-, radio-, and hormone therapy was entered, which
were considered possible explanatory variables. Assump-
tions underlying the multivariable Cox regression analysis
were met (e.g., visual inspection of the KM curve allowed
confirmation of the Cox proportional hazard assumptions).
We tested effect modifications for age, traditional car-
diovascular risk factors, and cancer treatment (chemo-,
radio-, and hormone therapy) by adding interaction terms
(i.e., depression/anxiety*age/traditional cardiovascular
risk/cancer treatment) to the fully adjusted model. We
examined whether the effect of anxiety and depression on
CVD risk differed by age (B65 vs[65 years at the time of
cancer diagnosis), traditional cardiovascular risk factors,
chemotherapy, radiation, or hormonal treatment. Missing
data were handled in previous steps and described else-
where [20]. All statistical tests were two-sided with alpha
set at 5%. We chose not to use a more stringent alpha level
since this is the first study relating both pharmaceutically
treated anxiety and depression to CVD risk in a sample of
breast cancer survivors, and hence we wanted to avoid




Of the 7889 eligible breast cancer survivors, 515 were
excluded as they received prescribed CVD medications in
the 12 months before or after their cancer diagnosis, and
147 were excluded as they were deceased or lost to follow-
up in the first year after cancer diagnosis. After exclusion,
7227 1-year breast cancer survivors were included in sta-
tistical analyses.
The 1-year breast cancer survivors who developed CVD
differed from those who did not (Table 1)—that is—they had
a 1-year shorter follow-up period, had higher mortality rates,
used more often drugs for anxiety and traditional cardiovas-
cular risk factors (i.e., hypertension, hypercholesterolemia,
Breast Cancer Res Treat (2017) 166:259–266 261
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diabetes mellitus) in the year prior to their cancer diagnosis,
and were treated less often with chemo-, radio-, and hormone
therapy (all p’s\0.05).
Associations with CVD risk
Analyzing the associations between anxiety and depression
present in the year prior to cancer diagnosis with CVD risk
separately (data not shown) showed that anxiety in the year
prior to cancer diagnosis was associated with an increased
risk for incident CVD in all models: age-adjusted [hazard
ratio (HR) = 1.58; 95% confidence interval (95% CI)
1.13–2.20], partially adjusted (adjusted for age and CVD
risk factors) [HR = 1.45; 95% CI 1.04–2.03], and fully
adjusted model [HR = 1.46; 95% CI 1.04–2.04). Surpris-
ingly, depression was not significantly associated with
CVD risk in any of the models (data not shown).
When adding both anxiety and depression simultane-
ously to the model (Table 2), anxiety remained associated
with an increased risk for incident CVD [HR = 1.60; 95%
CI 1.13–2.25], while controlling for depression. The
adjustment for traditional cardiovascular risk factors
slightly attenuated the effect of anxiety but remained sig-
nificant [HR = 1.47; 95% CI 1.04–2.07]. This did not
change after adding information on tumor stage and treat-
ment to the model [HR = 1.48; 95% CI 1.05–2.08]. Hence,
women who were anxious in the year prior to their cancer
diagnosis had a 48% increased CVD hazard after adjust-
ment for depression, traditional cardiovascular risk factors,
and clinical factors. Depression was not associated with
incident CVD in any of the models (Table 2).
Older age [HR = 1.06; 95% CI 1.05–1.08], taking
medication for hypertension [HR = 1.80; 95% CI
1.32–2.46], and hypercholesterolemia [HR = 1.63; 95%
CI 1.15–2.33] were associated with an increased hazard for
incident CVD, whereas being treated with hormone therapy
[HR = 0.59; 95% CI 0.42–0.83] was protective for CVD
(Table 2). Taking medication for depression or diabetes
mellitus, tumor stage, chemo- and radiotherapy were not
associated with CVD risk (Table 2).
There were no cancer treatment moderation effects for
anxiety on CVD risk, nor were there significant interaction
effects with traditional cardiovascular risk factors. There
was an age-related significant interaction effect with
anxiety [HR = 0.84; 95% CI 0.74–0.96], where there
remained a significant main effect of anxiety [HR = 2.04;
95% CI 1.36–3.06] on CVD risk. Stratified analyses
showed that the association was restricted to women who
were B65 years at breast cancer diagnosis [HR = 2.29;
95% CI 1.31–4.02], as there was no increased CVD risk
among older survivors [HR = 1.24; 95% CI 0.80–1.93]
(Fig. 1).
Discussion
This population-based observational study showed that
pharmaceutical therapy for anxiety but not depression in
the year prior to breast cancer diagnosis was associated
with an increased hazard of incident CVD in 1-year breast
cancer survivors. This relation remained significant after
adjustment for depression, traditional cardiovascular risk
factors, and clinical characteristics, and was restricted to
younger breast cancer patients. Associations did not differ
by type of cancer treatment or the presence of traditional
cardiovascular risk factors in the year prior to breast cancer
diagnosis.
The association between pharmaceutical treatment for
anxiety present in the year prior to cancer diagnosis and the
increased risk for CVD found in the current study is con-
sistent with studies in healthy individuals, showing that
anxiety predicts the onset of CVD [11, 12]. We focused on
pharmaceutically treated anxiety and depression prior to
breast cancer to examine whether anxiety and depression
prior to the major life event of a breast cancer diagnosis are
related to an increased risk of CVD. However, we know
that being diagnosed with cancer and undergoing treatment
is known to have a major impact on one’s life, as many
cancer survivors experience feelings of anxiety or depres-
sion [23, 24]; hence, an additional proportion of breast
cancer survivors may start to use pharmaceutical treatment
for anxiety. We found a higher increased risk for anxiety in
our study (48%) than a meta-analysis among healthy
individuals did (26%) [12]. The increased risk of anxiety in
our study remained statistically significant despite adjust-
ment for hypertension, hypercholesterolemia, diabetes
mellitus, tumor stage, and received chemo-, radio-, or
hormone therapy. Hence, this association seems not to be
driven by the presence of traditional cardiovascular risk
factors, cancer stage, or cancer treatment. It is interesting
that anxiety is only associated with an increased CVD risk
in younger survivors (B65 years). This is in line with
previous research where psychological factors especially
seem to play a role among younger individuals, whereas
among older individuals aging—and likely physiological
factors related to the aging and disease process—is sug-
gested to drive the relationship with poor health outcomes
[25]. Several behavioral and pathophysiological mecha-
nisms have been suggested to underlie the associations
between anxiety and increased CVD risk in non-cancer
populations. Anxiety has, for example, been related to
unhealthy lifestyle behaviors such as smoking and limited
exercise [26]. Furthermore, the autonomous nervous sys-
tem and hypothalamic–pituitary–adrenal axis known for
their role in the pathogenesis of CVD [27, 28] have been
suggested to be involved, as anxious individuals have a
262 Breast Cancer Res Treat (2017) 166:259–266
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lower heart rate variability [29] and higher cortisol levels
[30]. As medication use was used as a proxy for both
anxiety and CVD, we cannot rule out that the association
may partly be explained by a pharmacokinetic interaction
between both drug types, although little is known about this
association and the usage of anxiolytics is common among
CVD populations [31, 32].
The lack of an association between depression and CVD
risk was unexpected, as previous studies have demon-
strated that depression is a risk factor for both incident
CVD and CVD progression [11, 13–15]. This dissimilarity
could be because often other studies have examined either
depression or anxiety, and hence they are unable to dis-
entangle the role of each of depression and anxiety sepa-
rately and together. Alternatively, the result of the low
prevalence of pharmaceutically treated depressed individ-
uals in our study (8%) could play a role in us not con-
firming previous results. Using drug dispense information
as an indicator of depression, we could be underestimating
the true prevalence of depression, as a depression and its
milder form depressive symptoms are often not treated
with medication. Alternatively, depression may comprise
different subtypes. It has been suggested that some mani-
festations of depression may partly reflect cardiac disease
severity [33], and hence it may have distorted the strength
of the previously found associations between depression
and prognosis of CVD. Nevertheless, the fact that anxiety,
but not depression, was significantly associated with
increased CVD risk is in line with previous findings
studying poor outcomes among CVD populations [34–36].
Surprisingly, there was no effect of chemo- or radio-
therapy on CVD risk, despite the known cardiotoxicity of
these treatments [3, 4]. This finding may be attributed to
the lack of detailed information about type and dose of
systemic therapy given. As not all chemotherapeutic agents
are equally cardiotoxic, cardiotoxicity of chemo- and
radiotherapy is dose dependent [3]. It is thus possible that
grouping all chemotherapeutic agents irrespective of type
Table 1 Patient characteristics
of 7227 1-year breast cancer
survivors stratified by CVD
status
CVD (n = 193) No CVD (n = 7034)
Follow-upb time in median years (range) 3 (0–13) 4 (0–13)*
Deceased 53 (28) 1077 (15)*
Demographics
Age in median years (range) 70 (46–91) 60 (23–102)*
Psychological factors
Anxiety 45 (23) 976 (14)*
Depression 15 (8) 553 (8)
Traditional CVD risk factorsa 118 (61) 2214 (32)*
Hypertension 106 (55) 1892 (27)*
Hypercholesterolemia 49 (25) 810 (12)*
Diabetes mellitus 21 (11) 398 (6)*
Clinical characteristics
Tumor stage
1 93 (49) 3119 (45)
2 80 (42) 2819 (41)
3 14 (7) 761 (11)
4 3 (2) 223 (3)
Cancer treatment
Surgery 184 (95) 6677 (95)
Chemotherapy 29 (15) 2661 (38)*
Radiation 123 (64) 5042 (72)*
Hormone therapy 72 (37) 3392 (48)*
Information is provided in numbers (n) with percentages for categorical variables, whereas follow-up time
and age are presented in median years (range). CVD = cardiovascular disease. Psychological and traditional
CVD risk factors = being pharmaceutically treated in the 12 months prior to breast cancer diagnosis
a Being pharmaceutically treated for at least one of the traditional cardiovascular risk factors (hypertension,
hypercholesterolemia, diabetes mellitus) during the 12 months prior to cancer diagnosis, yes/no
b Follow-up for a diagnosis of CVD began 12 months after cancer diagnosis, as primary cancer treatment is
generally finalized within the first year
*Significant difference (p\ 0.05) between those with and without CVD
Breast Cancer Res Treat (2017) 166:259–266 263
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and dosage will result in an underestimation of their true
effect. Moreover, we found a protective effect of hormonal
cancer treatment on CVD risk. A previous study also found
that hormone treatment in breast cancer survivors can
lower the risk of CVD, yet only several years after diag-
nosis, as it increases the risk of CVD in the first years after
cancer diagnosis [37]. Previous studies have suggested that
estrogen hormone treatment has favorable effects on
lipoproteins, coronary arteriosclerosis, endothelial func-
tion, and arterial thrombosis [37]. Exploratory post hoc
analyses, indeed, showed a protective effect of hormone
treatment on incident CVD 6–10 years after cancer diag-
nosis in our sample, whereas there was no significant
relation in the first 5 years after diagnosis or
after C11 years.
A general limitation inherent to the observational study
design is the lack of information on residual confounders.
Furthermore, we used drug dispense information as a proxy
for anxiety, depression, and CVD. We did not have addi-
tional information on medical diagnosis or patient-reported
information on anxiety or depression. Nevertheless, algo-
rithms based on pharmacy drugs are known to be more
specific, yet less sensitive than medical diagnoses [38].
Also, we used a rather tight algorithm to define CVD, as
this was based on a minimum of two C01 drug dispenses
within 6 months, possibly leading to an underestimation of
the incidence of CVD. It is also possible that we missed
CVD patients who use other drugs, such as ACE inhibitors
or beta-blockers but no C01 drug, although we expect this
Table 2 Associations between
pharmaceutically treated
anxiety and depression with
incident CVD risk after breast
cancer diagnosis
Age-adjusted model Partially adjusted model Fully adjusted model
HR (95% CI) HR (95% CI) HR (95% CI)
Psychological factors
Anxiety 1.60 (1.13–2.25)* 1.47 (1.04–2.07)* 1.48 (1.05–2.08)*
Depression 0.91 (0.53–1.57) 0.90 (0.53–1.55) 0.89 (0.52–1.53)
Demographics
Age (continuous) 1.07 (1.06–1.08)* 1.06 (1.05–1.08)* 1.06 (1.05–1.08)*
Traditional CVD risk factors
Hypertension – 1.77 (1.29–2.42)* 1.80 (1.32–2.46)*
Hypercholesterolemia – 1.77 (1.29–2.42)* 1.63 (1.15–2.33)*
Diabetes mellitus – 1.02 (0.63–1.64) 1.05 (0.65–1.69)
Clinical characteristics
Tumor stage
Stage I (reference) – – –
Stage II – – 1.14 (0.81–1.61)
Stage III – – 0.97 (0.52–1.80)
Stage IV – – 0.93 (0.29–3.05)
Cancer treatment
Chemotherapy – – 1.05 (0.65–1.69)
Radiation – – 0.78 (0.57–1.06)
Hormone treatment – – 0.59 (0.42–0.83)*
Information is provided in hazard ratios (HR) with 95% confidence intervals (95% CI). Partially
adjusted = adjusted for age and the traditional cardiovascular risk factors (i.e., hypertension, hyperc-
holesterolemia, and diabetes mellitus) present in the 12 months prior to cancer diagnosis; fully
adjusted = adjusted for traditional cardiovascular risk factors and clinical information (tumor stage and
treatment information, that is chemotherapy, radiation, and hormone treatment). Psychological and tradi-
tional CVD risk factors = being pharmaceutically treated in the 12 months prior to breast cancer diagnosis.
*p\ 0.05
Fig. 1 Association between pharmaceutically treated anxiety and
incident CVD among younger (B65 years) and older ([65) women
(age at breast cancer diagnosis). Note CVD = cardiovascular disease,
p = p value; *p\ 0.05
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number to be small. In addition, as we were interested in
incident CVD, breast cancer survivors with CVD in the
year prior to their cancer diagnosis were excluded. Hence,
we are looking at a subpopulation of 1-year breast cancer
survivors.
Strengths of our study include the large population-
based sample of breast cancer survivors and the usage of
high-quality databases of the Netherlands Cancer Registry
and PHARMO enabling a 13-year follow-up period.
Additionally, this is to our knowledge the first study that
examined the association between pharmaceutically treated
anxiety and depression with incident CVD among breast
cancer survivors. Furthermore, we estimated CVD risk 1
year after breast cancer diagnosis, striking a compromise
between not starting too late and missing incident CVD due
to ongoing cancer treatment or increased clinical checkups.
In conclusion, 1-year breast cancer survivors with
pharmaceutically treated anxiety in the year prior to their
cancer diagnosis had a 48% increased risk of incident
CVD, after adjustment for depression, traditional cardio-
vascular risk factors, tumor stage, and cancer treatment.
This increased risk seems to be limited to those breast
cancer survivors who were 65 years or younger at cancer
diagnosis. Depression was not related to an increased risk
of incident CVD. Future studies unraveling these associa-
tions are warranted in order to provide the best optimal care
for women treated for breast cancer.
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